Navigation Links
Drug developed by Hebrew U. and others holds promise for treatment of wounds
Date:2/16/2011

Jerusalem, February 7, 2011 -- A low cost, nanometer-sized drug to treat chronic wounds, such as diabetic foot ulcers or burns, has been developed by a group of scientists from the Hebrew University of Jerusalem, Harvard Medical School and others in the U.S. and Japan.

Diabetes is a rapidly growing medical problem affecting close to 3 percent of the world's population. Poor blood circulation arising from diabetes often results in skin wounds which do not heal, causing pain, infection and at times amputation of limbs.

Several proteins, called growth factors, have been found to speed up the healing process, however purifying these growth factor proteins is very expensive, and they do not last long on the injured site.

Now, scientists at the Hebrew University and Harvard involved in the project have used genetic engineering to produce a "robotic" growth factor protein that responds to temperature. Increasing the temperature causes dozens of these proteins to fold together into a nanoparticle that is more than 200 times smaller than a single hair.

This behavior greatly simplifies protein purification, making it very inexpensive to produce. It also enables the growth factor to be confined and to remain at the burn or wound site. The scientists refer to their discovery as robotic, since just as robots are machines that respond to their environment by carrying out a specific activity, so too this protein they have developed responds and reacts to heat.

The experimental drug, which ha been developed by the research group as a topical ointment, has been patented and thus far has been used to treat chronic wounds in diabetic mice, dramatically increasing the healing rate. The goal is to proceed to human clinical trials at some future date after future tests and refinements.


'/>"/>

Contact: Jerry Barach
jerryb@savion.huji.ac.il
972-258-82904
The Hebrew University of Jerusalem
Source:Eurekalert  

Page: 1

Related biology technology :

1. Human Trial Results Show Plant Extract Tops Drug at Regulating Blood Sugar Levels; Huge Market Seen for Newly Developed Food Additive Emulin™
2. FDA Approves Clinical Studies of a Novel Anti-Cancer Drug Developed by Italian Researchers
3. Designer molecules being developed to fight disease
4. SAFC Supply Solutions(R) Announces Raw Materials Line Developed Specifically to Meet Molecular Diagnostics Manufacturing Requirements
5. New Sigma Advanced Genetic Engineering Labs Offers Research Community Unique Rodent Models Developed Using Exclusive Gene-Editing Technology
6. QIAGENs New Product Line, QIAsafe(R) DNA Blood, has Been Co-Developed With Biomatrica and is Based on Biomatricas SampleMatrix(R) Technology
7. NovaBay(R) Presents Data Confirming Its Aganocide(R) Compounds Are Effective In Killing Bacteria That Have Developed Multidrug-Resistance
8. New lab-on-a-chip technique developed at U of T
9. New nanotech sensor developed with medical, chemistry applications
10. New Program Developed in the Fight Against Feline Aids
11. DuPont Leader: Drought-Tolerant Crops Developed Through Modern Breeding are Key to Sustainably Increasing Grain Production
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug developed by Hebrew U. and others holds promise for treatment of wounds
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the ... at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application ... team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... the trading session at 4,833.32, down 0.22%; the Dow Jones ... the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ... BIND Therapeutics Inc. (NASDAQ: BIND ). Learn more ...
Breaking Biology Technology:
(Date:6/16/2016)... SAN FRANCISCO , June 16, 2016 /PRNewswire/ ... Market size is expected to reach USD ... report by Grand View Research, Inc. Technological proliferation ... and banking applications are expected to drive the ... ) , The development of ...
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the medical ... premium product recently added to the range of products distributed by Ampronix. ... ... ... Ampronix News ...
Breaking Biology News(10 mins):